The efficacy of PARP1/2 inhibitors has also previously been demonstrated in AML18, ALL cell lines19, and other pre-clinical leukemic models20, however their usage for pediatric ALL with elevated PARP abundance has not yet been shown. Here, PARP1 is linked to acute lymphoblastic leukemia.